In a major oncology development, the U.S. FDA has accepted a supplemental application for Datroway (datopotamab deruxtecan). It has been granted Priority Review as a first-line therapy for adults with metastatic triple-negative breast cancer who cannot receive immunotherapy.
In a major oncology development, the U.S. FDA has accepted a supplemental application for Datroway (datopotamab deruxtecan). It has been granted priority review as a first-line therapy for adults with metastatic triple-negative breast cancer who cannot receive immunotherapy.
The regulatory decision marks an important milestone in cancer treatment. Datroway has shown meaningful survival benefits compared with standard chemotherapy for this aggressive cancer subtype. Additionally, the Priority Review designation expedites the FDA’s assessment. This step highlights the urgent need for more effective first-line options in patients ineligible for PD-1 or PD-L1 therapies.
Under the Prescription Drug User Fee Act, priority review shortens the review timeline. Datroway could offer a substantial improvement in safety or effectiveness over existing options. If approved, it may change clinical practice by providing a new first-line treatment for patients with unresectable or metastatic triple-negative breast cancer. The FDA’s target action date is in the second quarter of 2026.
The decision is based on results from the global, randomized TROPION Breast Phase III trial. This trial compared Datroway with physician-chosen chemotherapy regimens. Datroway extended median overall survival by approximately five months. It also reduced the risk of disease progression or death by 43% compared with chemotherapy. These findings demonstrate that Datroway (datopotamab deruxtecan) may provide durable clinical benefits in a patient population with limited options.
Importantly, Datroway produced a higher objective response rate and longer duration of response than chemotherapy. Patients treated with Datroway achieved a 62.5% response rate. Median duration of response exceeded 12 months, compared with 29% and seven months in the chemotherapy group. These results suggest Datroway may deliver meaningful and sustained tumor control in the first-line setting.
AstraZeneca and Daiichi Sankyo, developers of Datroway, emphasized the therapy’s potential impact. Executives stated that it could become the first treatment to significantly improve both survival and progression metrics. In some patients, it nearly doubles the time without disease progression or death compared with current chemotherapy.
Triple-negative breast cancer (TNBC) accounts for roughly 15% of all breast cancer cases. It is one of the most aggressive subtypes, with a median overall survival between 12 and 18 months. Unlike hormone receptor-positive or HER2-positive cancers, TNBC lacks targets for many approved therapies. Chemotherapy remains the only approved first-line option for patients who cannot receive immunotherapy. The continual introduction of new therapies worldwide by established companies contributes to advancements in treatment options. Additionally, the expanding pipeline of breast cancer treatments is intensifying research activity and encouraging further investment in therapeutic development.
The Priority Review also occurs under Project Orbis, an international regulatory collaboration. This framework allows concurrent submission and review of cancer treatments across participating agencies. It accelerates access to promising therapies such as Datroway in multiple regions simultaneously.
Susan Galbraith, Executive VP of Oncology R&D at AstraZeneca, said Datroway is the only treatment in this population demonstrating a significant overall survival advantage compared to chemotherapy. She added that the Priority Review highlights the strength of clinical results and the urgent need for improved frontline options.
Ken Takeshita, Global Head of R&D at Daiichi Sankyo, highlighted that Datroway may become the first therapy to markedly improve survival for patients unsuitable for immunotherapy. He emphasized that both companies look forward to collaborating with regulators to bring this therapy to patients quickly.
Datroway (datopotamab deruxtecan) belongs to a class of targeted therapies called antibody-drug conjugates (ADCs). These combine a monoclonal antibody that targets a specific protein, TROP2, with a cytotoxic agent, delivering chemotherapy directly to tumor cells while sparing healthy tissue.
Already approved in over 40 countries for advanced breast cancer and under accelerated approval in the U.S. for metastatic EGFR-mutated non-small cell lung cancer, Datroway’s development program includes multiple trials. These studies are evaluating its efficacy across various tumors and treatment settings.
As the FDA review continues, the oncology community and patients are watching closely. Many hope that Datroway will provide a much-needed new standard of care for patients with aggressive, difficult-to-treat breast cancer.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.